Market Overview

UPDATE: Canaccord Maintains Sell On Meridian Bioscience, Lowers Target To $9 As Firm Believes 'the turnaround is not near-term and, if one is possible, it is likely at least 2-3 years away'

Share:

This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of headlines on any catalyst that could move the stocks you care about on Benzinga Pro, our flagship platform for fast, actionable information that promotes faster, smarter trading.

Benzinga Pro has an intuitively designed workspace that delivers powerful market insight, and is the solution of choice for thousands of professional and retail traders across the world.

Stop Googling for information and check out Benzinga Pro. You will never again be left in the dark on when a stock moves. You’ll have what you need to act in real-time — before the crowd.

Start your FREE 14-day trial of Benzinga Pro today.

Latest Ratings for VIVO

DateFirmActionFromTo
May 2019MaintainsSellSell
May 2019UpgradesUnderweightNeutral
Apr 2019DowngradesHoldSell

View More Analyst Ratings for VIVO
View the Latest Analyst Ratings

Posted-In: Analyst Color News Price Target Reiteration Analyst Ratings

 

Related Articles (VIVO)

Latest Ratings

StockFirmActionPT
PFSIPiper JaffrayMaintains40.0
CYDYHC Wainwright & Co.Reiterates1.0
APTSNational SecuritiesInitiates Coverage On18.0
ESPRGoldman SachsUpgrades45.0
CARSCraig-HallumUpgrades15.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Q1 Earnings Outlook For MetLife

Hologic's Q2 Earnings Preview